Biao Wang, et al. v. Zymergen Inc., et al.

District Court, N.D. California·Decided October 22, 2025·No. 5:21-cv-06028·Unknown

Opinion

BIAO WANG, et al., Case No. 21-cv-06028-PCP (SVK)

Plaintiffs, ORDER ON PLAINTIFFS’ MOTION FOR RECONSIDERATION OF v. FEBRUARY 21, 2025 ORDER RE ZYMERGEN DEFENDANTS’ ZYMERGEN INC., et al., PRIVILEGE ISSUES Defendants. Re: Dkt. No. 595

Before the Court is the latest in a long series of Plaintiffs’ challenges to the assertion of the attorney-client privilege by Defendant Zymergen, Inc., now the ZYM Liquidating Trust (“Zymergen” or “Trust”). See Dkt. 442, 483, 500, 501. In light of recent events, Plaintiffs seek reconsideration of this Court’s February 21, 2025 order (Dkt. 524 – the “February Order”) overruling various challenges and upholding the privilege. Dkt. 595 (“Motion”). The Trust and the Individual Defendants1 oppose the motion. Dkt. 599, 600. On October 7, 2025 the Court held a lengthy hearing on the Motion and took the matter under submission. Plaintiffs’ numerous arguments in support of reconsideration are based upon a handful of new facts:

1 The Individual Defendants comprise former officers and directors of Zymergen. In November 2021, the Individual Defendants included: Steven Chu, Jay Flatley, Christine Gorjanc, Josh Hoffman, Travis Murdoch, Matthew Ocko, Sandra Peterson, Zach Serber, Rohit Sharma and Enakshi Singh. Dkt. 561-2. Defendants Singh and Hoffman retained separate counsel in 2023, and counsel appeared at the October 7 hearing. In the Motion, at times Plaintiffs refer to the Individual Defendants and Director Defendants interchangeably. In the context of the Motion, it is a distinction without a difference, and for consistency the Court uses the all-inclusive Individual Defendants. 1. A WilmerHale partner recently submitted a declaration stating that in September 2024, prior to the privilege issues being brought to this Court, WilmerHale informed the Trust that there was a potential conflict in its dual representation of Zymergen and the Individual Defendants. S. Muck Declaration in Support of Wilmer-Hale Motion to Withdraw, Dkt. 561, 561-1. 2. On June 6, 2025, the Trust sued the Director Defendants, a subset of the Individual Defendants in this action, in state court (the “State Court Action”), alleging breach of fiduciary duties arising out of the same core facts as Plaintiffs have asserted in this action. Dkt. 557-2. 3. The Individual Defendants served expert reports after the February Order that, according to Plaintiffs, reflect privileged attorney-client communications such that either the documents must be produced or affirmative defenses stricken. Dkt. 596-5; 596-6. 4. At least by July 2025, Zymergen’s insurance coverage for this litigation had been exhausted, and, in accordance with the terms of its bankruptcy plan, Zymergen is now immune from further litigation, which Plaintiffs argue extinguishes any privilege. Trust’s Motion to Intervene, Exhibit C, Dkt. 564-4. The Court addresses the first, second and third of these developments in sections I and II below; the fourth development is addressed in section III. I. THE TERMINATION OF THE COMMON-INTEREST PRIVILEGE BETWEEN ZYMERGEN (AKA THE TRUST) AND THE INDIVIDUAL DEFENDANTS AND A. Relevant Background The Motion contains a detailed and largely uncontested history of the privilege issues, including proceedings before this Court, which will not be repeated here. Dkt. 595 at 3-12. The salient facts for this discussion are: • In August 2021 Plaintiffs sued Zymergen, the Individual Defendants and others in this action for violations of §§11, 15 of the Securities Act. Dkt. 1. • In November 2021 WilmerHale undertook dual representation of Zymergen and the Individual Defendants. Dkt. 561-2 (WilmerHale engagement letter). • In October 2023 Zymergen filed for Chapter 11 Bankruptcy (S. Muck Declaration in Support of WilmerHale Motion to Withdraw, Ex. B; Dkt. 561-3) with the following effects: o WilmerHale was directed to continue its representation of Zymergen (and the Individual Defendants) in this action. Muck Decl. Ex. D, Dkt. 561-5. o Zymergen’s privileges were expressly transferred to the Trustee. 2 Trust Opposition (Dkt. 599 at 4), citing Dkt. 501-6 (Liquidating Trust Agreement). • The challenged privileged documents are all from the time frame December 2020 to May 2022, predating Zymergen’s filing for bankruptcy. Individ. Defs. Oppo. to Motion, fn. 4, Dkt. 600; 10/5/25 Hrg. Transcript, pp. 11-16. • Throughout the present litigation, WilmerHale has asserted a common-interest privilege on behalf of Zymergen and the Individual Defendants.3 • WilmerHale recently moved to withdraw as counsel for the Trust in this action (Dkt. 561), stating in support of that motion that in September 2024, WilmerHale informed the Trust that there was a potential conflict in its dual representation of Zymergen and the Individual Defendants. S. Muck Decl. in Support of WilmerHale Motion to Withdraw, Dkt. 561-1. • As noted above, on June 6, 2025, the Trust sued the Individual Defendants in state court, alleging breach of fiduciary duty, unjust enrichment and waste of corporate assets, arising out of the same core facts as alleged in this action. Dkt. 557-2. From these facts, Plaintiffs argue that any common-interest privilege as between the Trust and the Individual Defendants terminated no later than September 2024, and the continued sharing

2 In past proceedings before this Court, WilmerHale affirmed that it was acting at the direction of the Trustee, in addition to the Individual Defendants. Dkt. 523, 523-1.

Free access — add to your briefcase to read the full text and ask questions with AI

Biao Wang, et al. v. Zymergen Inc., et al., (N.D. Cal. 2025).

Biao Wang, et al. v. Zymergen Inc., et al. (Biao Wang, et al. v. Zymergen Inc., et al.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related